RFG Advisory LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 12,407 shares of the biotechnology company’s stock, valued at approximately $532,000.
Several other large investors have also recently added to or reduced their stakes in EXEL. Motiv8 Investments LLC acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $26,000. Anchor Investment Management LLC raised its stake in shares of Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Acumen Wealth Advisors LLC bought a new position in Exelixis in the fourth quarter worth $29,000. Activest Wealth Management bought a new position in Exelixis in the fourth quarter worth $32,000. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after buying an additional 773 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.
Analysts Set New Price Targets
EXEL has been the topic of several analyst reports. Zacks Research lowered shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Stifel Nicolaus lifted their target price on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Royal Bank Of Canada lowered their target price on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. Morgan Stanley reissued a “positive” rating on shares of Exelixis in a research report on Monday, June 22nd. Finally, Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $46.87.
Insider Buying and Selling at Exelixis
In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the sale, the director directly owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. The trade was a 1.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 219,170 shares of company stock worth $10,620,641 over the last ninety days. Company insiders own 2.60% of the company’s stock.
Exelixis Price Performance
Shares of NASDAQ:EXEL opened at $54.28 on Tuesday. The business’s fifty day moving average price is $49.78 and its two-hundred day moving average price is $45.61. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $55.91. The stock has a market capitalization of $13.64 billion, a price-to-earnings ratio of 18.03, a price-to-earnings-growth ratio of 1.58 and a beta of 0.41.
Exelixis (NASDAQ:EXEL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. During the same period last year, the business earned $0.55 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. Research analysts expect that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.
Exelixis Profile
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Featured Articles
- Five stocks we like better than Exelixis
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
